📢 New Review in #LiversMDPI

🧬 Lonardo et al. review liver fibrosis assessment, management, and prevention.

🩺 Fibrosis can regress when the injurious stimulus is controlled, notably at F0–F2.

📖 Read More: www.mdpi.com/2673-4389/6/...

#LiverFibrosis #Cirrhosis

#MASLD patients with high cardiovascular risk have more severe #liverfibrosis and higher risk of liver complications, highlighting the need for integrated cardiometabolic and hepatic care.

🔗: https://ow.ly/13B050ZTbXX

Targeting RPL4 in combination with PD-L1 blockade achieves near-complete resolution of liver fibrosis.

#LiverFibrosis #LiverSky #Hepatology
https://doi.org/10.1016/j.xcrm.2026.103056

Researchers at the McGill University Health Centre, including CTN+ scientist Dr. Sebastiani, have developed a new method for screening for #LiverFibrosis among HIV patients which they say are more effective compared to the commonly used test.

Read more: https://tinyurl.com/ms3np265

PAK4 phosphorylates YAP at T428, promoting its stabilization, nuclear accumulation and transcriptional activity to drive #HepaticStellateCell activation, while genetic or pharmacological PAK4 inhibition attenuates #LiverFibrosis.

#STTT #OpenAccess: doi.org/10.1038/s413...

🫀“Energy metabolism: An emerging therapeutic frontier in liver fibrosis” @hospitaluvrocio.bsky.social @ibis-investigacion.bsky.social.

👉 Disponible en #risalud hdl.handle.net/10668/31504

#BVSSPA #EnergyMetabolism #LiverFibrosis

Hepatic stellate cells (HSCs) represent an important source of cancer-associated fibroblasts (CAFs) in HCC.

#LiverFibrosis #LiverSky #Hepatology
https://doi.org/10.3389/fimmu.2026.1930718